Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eytan Breman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|July 4, 2024
Engineering strategies to safely drive CAR T-cells into the futureMatteo Rossi, Eytan Breman
Cells|January 22, 2024
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Caroline Lonez, Eytan Breman
International Journal of Molecular Sciences|February 26, 2025
Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-CellsCaroline Lonez, Jennifer Bolsée, Fanny Huberty, et al.
Molecular Therapy. Nucleic Acids|October 6, 2023
Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platformMatteo Rossi, Mikhail Steklov, Fanny Huberty, et al.
Kidney International|October 25, 2017
Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cellsJurjen M Ruben, Gina Stella García-Romo, Eytan Breman, et al.
Journal of Immunology Research|July 15, 2016
Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect AllorecognitionEytan Breman, Jurjen M Ruben, Kees L Franken, et al.
Transplantation|May 7, 2014
HLA monomers as a tool to monitor indirect allorecognitionEytan Breman, Paula P van Miert, Dirk M van der Steen, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2022
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell TherapyAlexandre Michaux, Sébastien Mauën, Eytan Breman, et al.
Frontiers in Immunology|January 9, 2019
Overcoming Target Driven Fratricide for T Cell TherapyEytan Breman, Benjamin Demoulin, Sophie Agaugué, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|July 4, 2024
Engineering strategies to safely drive CAR T-cells into the futureMatteo Rossi, Eytan Breman
Cells|January 22, 2024
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Caroline Lonez, Eytan Breman
International Journal of Molecular Sciences|February 26, 2025
Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-CellsCaroline Lonez, Jennifer Bolsée, Fanny Huberty, et al.
Molecular Therapy. Nucleic Acids|October 6, 2023
Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platformMatteo Rossi, Mikhail Steklov, Fanny Huberty, et al.
Kidney International|October 25, 2017
Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cellsJurjen M Ruben, Gina Stella García-Romo, Eytan Breman, et al.
Journal of Immunology Research|July 15, 2016
Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect AllorecognitionEytan Breman, Jurjen M Ruben, Kees L Franken, et al.
Transplantation|May 7, 2014
HLA monomers as a tool to monitor indirect allorecognitionEytan Breman, Paula P van Miert, Dirk M van der Steen, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2022
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell TherapyAlexandre Michaux, Sébastien Mauën, Eytan Breman, et al.
Frontiers in Immunology|January 9, 2019
Overcoming Target Driven Fratricide for T Cell TherapyEytan Breman, Benjamin Demoulin, Sophie Agaugué, et al.
Pageof 1